Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Capital One Financial Corp. (COF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Capital One Financial Corp.Trade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Capital One Financial Corp. vs Zimmer Biomet Holdings Inc — how do they compare? Capital One Financial Corp. trades at $209.34 (market cap $126.46B), while Zimmer Biomet Holdings Inc trades at $91.8 (market cap $17.61B). The key difference: Capital One Financial Corp. is far larger — about 7.2× Zimmer Biomet Holdings Inc's market cap, and Capital One Financial Corp. pays the higher dividend (1.56%). Which is the better fit depends on your goals.

COFZBH
Market Cap
$126.46B$17.61B
Sector
FinancialsHealth
52-Week High
$257.94$107.71
52-Week Low
$176.10$79.58
Dividend Yield
1.56%1.05%
Enterprise Value
$24.66B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Capital One Financial Corp.

Capital One Financial (COF) trades at $203.02, up 0.74% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but strong revenue growth to $53.43B in 2025. Analyst consensus remains positive with a $252.40 price target and 62.5% buy ratings, while the Discover integration presents significant expansion opportunities amid credit risk concerns.

COF offers potential upside from current levels with Wall Street optimism around the Discover acquisition, though investors face headwinds from rising delinquencies and margin compression. The stock's valuation at 62.44 P/E appears elevated relative to modest ROE of 3.34%, requiring careful monitoring of integration execution and credit quality trends.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.

ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Capital One Financial Corp.

Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.

Read more on COF

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH